Prescriptions for attention deficit hyperactivity disorder (ADHD) medication have risen by 18% each year since the Covid-19 pandemic, according to new research from the University of Huddersfield and Aston University.
The study, published in BMJ Mental Health, found an increasing trend in ADHD prescriptions across every region in England, suggesting heightened awareness of the condition as a key factor. Researchers believe social media has played a role in encouraging more people to seek diagnosis and treatment, but they also caution that misinformation online could contribute to misconceptions about symptoms, diagnosis, and medication use.
Pandemic Impact and Prescription Growth
Another major factor identified in the study is the worsening of ADHD symptoms linked to the Covid-19 pandemic. The research calculated that prescription rates in England increased significantly from 25.17 items per 1,000 people in 2019/20 to 41.55 items in 2023/24, with an average national increase of 18% annually.
The study analysed English prescribing data for five licensed ADHD drugs:
- Stimulants: methylphenidate (Ritalin, Concerta, Delmosart), dexamfetamine, and lisdexamfetamine
- Non-stimulants: atomoxetine and guanfacine
Methylphenidate remained the most commonly prescribed medication, while lisdexamfetamine saw the highest growth rate at 55% annually.
Regional Variations in Prescriptions
While the overall trend showed growth, regional variations were notable. The lowest annual increase was recorded in the North East and Yorkshire (13%), while London experienced the highest rise at 28%.
Experts stress that ADHD medications are backed by substantial evidence demonstrating improvements in quality of life, cognitive function, and reductions in substance misuse. ADHD is characterised by symptoms such as inattention, hyperactivity, and impulsivity, often affecting a person’s ability to focus or remain still.
Calls for Expanded ADHD Services
Dr. Ulrich Muller-Sedgwick, ADHD champion at the Royal College of Psychiatrists, emphasised the importance of timely assessments and appropriate treatment.
“The right diagnosis and care, including medication and reasonable adjustments, can greatly benefit people’s health and support them to reach their full potential at school, university, or work,” he said.
He further highlighted the need for targeted investment in ADHD services to ensure individuals receive the care they require.
As awareness of ADHD continues to grow, the demand for diagnosis and treatment is expected to remain high, underscoring the importance of accessible and well-funded mental health services.